Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ONCT)

GTx Provides Corporate Update and Reports 2013 Financial Results

Business Wire March 4, 2014

GTx, Inc. Announces Pricing of Private Placement

Business Wire March 4, 2014

GTx Announces Webcast of Corporate Presentation at Cowen and Company 34th Annual Health Care Conference

Business Wire February 26, 2014

GTx, Inc. To Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast

Business Wire February 18, 2014

GTx Announces Webcast of Corporate Presentation at Bio CEO & Investor Conference

Business Wire February 4, 2014

Preliminary findings from the Phase 2 clinical trial of GTx-758 in men with castration resistant prostate cancer to be presented at ASCO Genitourinary Cancer Symposium

Business Wire January 29, 2014

GTx Presents on Enobosarm as Targeted Therapy for the Treatment of Androgen Receptor-Positive Breast Cancer at the San Antonio Breast Cancer Symposium

Business Wire December 12, 2013

GTx Provides Corporate Update and Reports Third Quarter 2013 Financial Results

Business Wire November 12, 2013

GTx, Inc. To Host Third Quarter 2013 Financial Results Conference Call and Webcast

Business Wire October 29, 2013

New Small Cap Stock Reports on NPHC, LQMT and GTXI

Accesswire October 29, 2013

GTx Presents Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer

Business Wire October 24, 2013

GTx Announces Late Breaker Presentation on Results from the two Phase 3 POWER Trials of enobosarm, a selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC patients during 2013 European Cancer Congress

Business Wire September 24, 2013

GTx Announces Webcast of Corporate Presentation at Stifel Nicolaus 2013 Healthcare Conference

Business Wire September 6, 2013

GTx, Inc. Sued by Investor

PR Newswire August 29, 2013

Glancy Binkow & Goldberg LLP Announces Investigation of GTx, Inc.

Business Wire August 20, 2013

Five Star Equities Issues New Research Reports on GTXI, NTLS, PNK and SUPN

Accesswire August 20, 2013

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of GTx Inc.

Business Wire August 19, 2013

GTXI SHAREHOLDER ALERT: The Law Firm of Wohl & Fruchter LLP Announces Investigation of GTX Inc.

Business Wire August 19, 2013

GTx Reports Results for Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer

Business Wire August 19, 2013

GTx Provides Corporate Update and Second Quarter 2013 Financial Results

Business Wire July 19, 2013